NYSE:MD
Pediatrix Medical Group, Inc.
A leading US distributor of medical equipment and supplies that leverages technology to optimize hospital revenue cycles.
Key Metrics
Investment Thesis
Bull Case
The dramatic turnaround in net income from losses in 2023-2024 to $165.4M profit in 2025 signals a stabilizing business model with strong operational cash generation. Investors can capitalize on the company's substantial liquidity, evidenced by $375.2M in cash and equivalents, which offers flexibility for strategic acquisitions or dividend growth. The large goodwill base suggests prior growth investments are now yielding returns as the revenue stream stabilizes around the $1.9B-$2.0B level.
Bear Case
The sharp decline in 2025 revenue to $1.91B from a peak of $2.01B indicates potential saturation or loss of market share that could persist despite recent profit recovery. The company's history of net losses in 2023 and 2024 raises concerns about the sustainability of current margins without continued aggressive cost-cutting measures. Heavy reliance on non-cash adjustments totaling $162.7M suggests earnings quality may be volatile and dependent on accounting treatments rather than pure operational growth.
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group is a specialty distributor of medical equipment, instruments, and supplies serving healthcare facilities across the United States. The company focuses on optimizing revenue cycles for hospitals and ambulatory surgery centers through its proprietary software solutions and supply chain management. With a strong cash position of $375.2M and significant goodwill from acquisitions, the firm provides critical operational support to the broader healthcare ecosystem.
Analysis
Management Discussion
Despite a volatile income trajectory with losses in 2023 and 2024, the company achieved a strong rebound in net profit of $165.4M for 2025, demonstrating operational resilience. Management has successfully managed cash flow from financing activities of -$107.5M primarily through share repurchases of $86.7M while maintaining a robust operating cash flow. The return to profitability suggests effective cost control and successful integration of prior acquisitions, though the revenue contraction warrants close monitoring.
Industry Overview
The US medical equipment distribution industry is a mature sector characterized by steady demand driven by an aging population and technological innovation in healthcare delivery. Companies in this space face intense competition from large conglomerates like Medline and McKesson, forcing them to differentiate through specialized product lines and superior customer service. Regulatory environments regarding pricing transparency and supply chain security continue to evolve, impacting the margins of all major players.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.97B | $1.99B | $2.01B | $1.91B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.97B | $1.99B | $2.01B | $1.91B |
| Operating Expenses | $1.80B | $1.99B | $2.08B | $1.71B |
| Operating Income | $172.7M | $7.3M | $-68.7M | $208.8M |
| G&A | $231.4M | $227.5M | $238.4M | $240.8M |
| Stock-Based Comp | $16.1M | $12.3M | $11.9M | $18.0M |
| D&A | $35.6M | $36.2M | $32.2M | $21.8M |
| Depreciation | $26.7M | $28.1M | $22.7M | $14.3M |
| Amortization | $6.4M | $5.6M | $7.1M | $5.7M |
| Other OpEx | $1.57B | $1.76B | $1.84B | $1.46B |
| Non-Operating Income | $-91.3M | $-55.7M | $-32.6M | $7.6M |
| Interest Expense | $39.7M | $42.1M | — | — |
| Pre-Tax Income | $81.4M | $-48.4M | $-101.3M | $216.4M |
| Income Tax | $18.8M | $12.0M | $-2.3M | $51.0M |
| Continuing Ops | $62.6M | $-60.4M | $-99.1M | $165.4M |
| Discontinued Ops | $3.8M | $0 | $0 | $0 |
| Net Income | $66.3M | $-60.4M | $-99.1M | $165.4M |
| Minority Interest | $-4.0K | $0 | $0 | $0 |
| Net to Common | $66.3M | $-60.4M | $-99.1M | $165.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $428.0M | $483.5M | $639.6M | $763.5M |
| Cash & Equivalents | $9.8M | $73.3M | $229.9M | $375.2M |
| Accounts Receivable | $296.8M | $272.3M | $260.0M | $229.7M |
| Other Current Assets | $121.4M | $137.9M | $149.7M | $158.6M |
| Long-Term Assets | $1.92B | $1.74B | $1.51B | $1.48B |
| PP&E (Net) | $73.3M | $75.6M | $39.2M | $39.2M |
| Goodwill | $1.53B | $1.38B | $1.24B | $1.26B |
| Operating Leases | $55.8M | $61.7M | $34.1M | $31.1M |
| Other LT Assets | $258.7M | $214.9M | $197.2M | $152.1M |
| Total Assets | $2.35B | $2.22B | $2.15B | $2.25B |
| Current Liabilities | $427.0M | $388.9M | $434.1M | $458.9M |
| Accounts Payable | $31.9M | $34.6M | $46.4M | $37.2M |
| Current Leases | $21.6M | $21.1M | $12.7M | $11.6M |
| Taxes Payable | $16.3M | $2.2M | $2.2M | $984.0K |
| Other Current Liab | $357.3M | $331.1M | $372.8M | $409.1M |
| Long-Term Liabilities | $1.03B | $981.8M | $953.7M | $921.9M |
| LT Operating Leases | $44.2M | $47.2M | $31.9M | $25.7M |
| Other LT Liab | $985.1M | $934.6M | $921.7M | $896.2M |
| Total Liabilities | $1.46B | $1.37B | $1.39B | $1.38B |
| Shareholders' Equity | $891.6M | $849.1M | $764.9M | $865.9M |
| Retained Earnings | $-89.1M | $149.5M | $-248.5M | $-83.2M |
| AOCI | $-3.7M | $2.2M | $-1.1M | $610.0K |
| Total L&E | $2.35B | $2.22B | $2.15B | $2.25B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $66.3M | $-60.4M | $-99.1M | $165.4M |
| Non-Cash Adjustments | $104.6M | $294.7M | $312.4M | $162.7M |
| Working Capital Changes | $-4.0M | $-97.0M | $-6.8M | $-57.0M |
| Cash from Operations | $166.9M | $137.3M | $206.6M | $271.1M |
| Cash from Investing | $-57.0M | $-48.2M | $-35.4M | $-18.3M |
| Share Buybacks | $88.5M | $919.0K | $1.7M | $86.7M |
| Cash from Financing | $-487.6M | $-25.7M | $-14.5M | $-107.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-377.6M | $63.4M | $156.7M | $145.3M |
| Beginning Cash | $387.4M | $9.8M | $73.3M | $229.9M |
| Ending Cash | $9.8M | $73.3M | $229.9M | $375.2M |
Frequently Asked Questions
How does Pediatrix Medical Group, Inc. make money?
The company primarily generates revenue through the distribution of medical devices and instruments to healthcare providers, alongside specialized services for optimizing patient billing and collections. Operations include direct sales of branded and generic medical products, as well as technology-enabled solutions that help clients manage their financial workflows efficiently. Recent acquisitions totaling $23.2M indicate a strategy of expanding product lines and geographic reach through strategic integration.
What are the main risks for MD?
The healthcare distribution sector is highly sensitive to reimbursement rate changes and regulatory shifts that could compress profit margins on high-volume products. Significant goodwill of $1.26B exposes the company to impairment risks if acquisition synergies fail to materialize or if the broader medical device market contracts. The recent decline in revenue from $2.01B in 2024 to $1.91B in 2025 highlights vulnerability to demand fluctuations and potential pricing power erosion.
What is MD's competitive advantage?
Pediatrix maintains a robust market position backed by substantial goodwill of $1.26B, reflecting a history of successful M&A that has expanded its catalog without proportional debt increases. The company's proprietary software platform creates high switching costs for clients by deeply integrating with their existing revenue cycle management systems. A healthy net cash flow from operations of $271.1M provides significant liquidity to fund further growth initiatives or weather industry downturns.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.